On Monday, Republic Services, Inc. (NYSE:RSG)’s shares inclined 0.65% to $42.87.
Republic Services, Inc. (RSG) declared that its Board of Directors has approved a 2-cent enhance in the Company’s regular quarterly dividend. The quarterly dividend of $0.30 per share will be paid on Oct. 15, 2015, to shareholders of record on Oct. 1, 2015.
Republic Services, Inc., together with its auxiliaries, provides non-hazardous solid waste collection, transfer, recycling, and disposal services for commercial, industrial, municipal, and residential customers in the United States. It operates through three segments: East, Central, and West.
Flotek Industries Inc (NYSE:FTK)’s shares gained 1.81% to $18.60.
Flotek Industries, Inc. (FTK) declared results for the three months ended June 30, 2015.
As stated on Form 10-Q filed with the U.S. Securities and Exchange Commission, Flotek stated that revenue for the three months ended June 30, 2015, was $87.0 million contrast to $105.3 million for the three months ended June 30, 2014 and $82.4 million for the first quarter of 2015. Second quarter, 2015 revenue raised 5.6% sequentially but reduced 17.4% when contrast to the same period in 2014. The decrease in year-over-year revenue was driven by the steep decline in oilfield activity; however, the enhance in sequential revenue was driven almost entirely by raised sales of Flotek’s Complex nano-Fluid® completion chemistries as the Company’s marketing campaign and new direct distribution model offered noteworthy revenue opportunities during the quarter.
For the three months ended June 30, 2015, the Company stated net income (not taking into account non-cash charges) of $1.1 million, or $0.02 per common share (fully diluted), contrast to net income of $11.0 million, or $0.20 per common share (fully diluted) for the same period in 2014 and a net loss of $1.5 million or $0.03 per common share (fully diluted) in the first quarter of this year.
Flotek Industries, Inc. develops and supplies oilfield products, services, and equipment to the oil, gas, and mining industries in the United States and internationally. Its Energy Chemical Technologies segment designs, develops, manufactures, packages, and markets specialty chemicals used in oil and gas well drilling, cementing, completion, stimulation, and production. This segment also constructs and manages automated material handling facilities; and manages loading facilities and blending operations for oilfield services companies.
At the end of Monday’s trade, Cavium Inc (NASDAQ:CAVM)‘s shares surged 3.59% to $71.62.
Cavium, Inc. (CAVM), a leading provider of semiconductor products that enable secure and intelligent processing for enterprise, data center, wired and wireless networking, declared financial results for the second quarter ended June 30, 2015.
Generally Accepted Accounting Principles (GAAP) Results
Net loss in the second quarter of 2015 was $6.4 million, or $(0.11) per diluted share, contrast to $13.9 million, or $(0.25) per diluted share in the first quarter of 2015. Gross margins were 64.1% in the second quarter of 2015 contrast to 64.8% in the first quarter of 2015. Total cash and cash equivalents were $122.0 million at June 30, 2015.
Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks in United States and internationally. It offers integrated semiconductor processors for wired and wireless networking, communications, storage, cloud, wireless, security, video, and connected home and office applications.
Seattle Genetics, Inc. (NASDAQ:SGEN), ended its Monday’s trading session with 2.35% gain, and closed at $45.70.
Seattle Genetics, Inc. ( SGEN) stated financial results for the second quarter and six months ended June 30, 2015. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization, regulatory and clinical development accomplishments, progress with other proprietary pipeline programs and antibody-drug conjugate (ADC) and other collaborator updates.
Recent ADCETRIS Highlights
- The U.S. Food and Drug Administration (FDA) filed the company’s supplemental BLA for use of ADCETRIS in the AETHERA setting for post-transplant consolidation treatment of Hodgkin lymphoma (HL) patients at high risk of relapse or progression. The FDA granted Precedingity Review and set a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2015.
- Stated data on ADCETRIS in the AETHERA setting, in diffuse large B-cell lymphoma (DLBCL) and in several other HL and non-Hodgkin lymphoma settings at multiple sessions during the American Society of Clinical Oncology (ASCO) 50th Annual Meeting and the 13thInternational Conference on Malignant Lymphoma (ICML). The data demonstrated the breadth of the ADCETRIS clinical development program and its broad potential in a range of CD30-expressing malignancies.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
